Polaris Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial for Patients with GlioblastomaPolaris lead biologic ADI-PEG 20 to be Evaluated Across Multiple International Trial SitesLARKSPUR, Calif. (BUSINESS WIRE) #GBMAGILE Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris.
Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With GlioblastomaLARKSPUR, Calif. (BUSINESS WIRE) #GBMAGILE Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and V.